David

David Therapeutics is a biotechnology company dedicated to developing transformative treatments for rare diseases, with a primary focus on NGLY1 deficiency. The company was founded by Matt Wilsey, whose daughter was the first person diagnosed with the condition, to accelerate research into the N-glycanase 1 pathway. David Therapeutics utilizes a collaborative research model, partnering with academic institutions and other biotech firms to identify small molecule and genetic interventions. Their approach centers on restoring cellular proteostasis and addressing the multi-systemic symptoms of deglycosylation disorders. By leveraging deep insights into the NGLY1 pathway, the company aims to provide the first disease-modifying therapies for patients with this ultra-rare genetic condition.